Clinical Trial Update: ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis [Phase 1, Phase 2]

View source ↗

Summary

Atsena Therapeutics reports ATSN-201 gene therapy for RS1-associated X-linked retinoschisis is in Phase 1/Phase 2 and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Retinoschisis

Drugs mentioned

• ATSN-201

Snippet

Sponsor: Atsena Therapeutics Inc. | Conditions: X-linked Retinoschisis | Phase 1, Phase 2 | Status: RECRUITING